Anlong Bio Completes Nearly RMB 100 Million Series B+ Financing and Files IPO Prospectus

Recently, Anlong announced the completion of nearly 100 million RMBB+This round of financing was invested by the Beijing Municipal Medical and Health Industry Investment Fund and the Beijing Shunyi Airport Economic Zone Industry Fund, with funding from both municipal and district levels. At the same time, the company has reached an international strategic cooperation agreement in the field of small nucleic acid drugs with a U.S. Nasdaq-listed enterprise, with a cooperation scale reaching hundreds of millions of dollars, marking Anlong's advancement in the international market.BDImportant breakthroughs have been made in cooperation.

In product developmentProgress，Anlong Biotech Advances Multiple Product Lines. For ophthalmic wet age-related macular degeneration (wAMD) The suprachoroidal gene therapy product has been completed.ⅡPhase Clinical Enrollment,and obtained the approval from the Center for Drug Evaluation (CDE) Approved to conduct Phase II clinical trial for diabetic retinopathy indication,Logo Company has mature R&D capabilities for the parallel development of multiple indications. In the research and development of innovative small nucleic acid drugs, it collaborates with Karon Technology on hepatitis B (HBV) The project has entered the clinical stage; the product in collaboration with Solara Healto has also initiated clinical application; currently, the company has established cooperative relationships with listed enterprises both in China and internationally across five product lines, and its technical capabilities and industrialization potential have gained widespread recognition from investors and partners.

From2021Since the year, the field of gene therapy has faced numerous challenges. Multiple incidents have occurred globally.AAVAfter a serious clinical accident involving vectors, the technology has been mainly limited to rare diseases. Multinational pharmaceutical companies have adjusted their strategies, industry investment has entered a low point, and financing for companies in China has become extremely difficult. The United StatesAdverumThe company's clinical accident, even more so, has givenAAVThe application prospects in chronic disease areas that can be ventured into (such as age-related wet macular degeneration and diabetic retinopathy) have brought significant uncertainty. Against this backdrop, the suprachoroidal drug delivery approach adopted by Anlong significantly reduces the risk of inflammation while ensuring efficacy, providing...AAVThe application of technology in this field provides key solutions. The gene therapy enterprises under Kanghong Pharmaceutical and Hengrui Pharmaceutical have successively adopted this approach, fully demonstrating the scientific value and application potential of this technical pathway.

With a long-term strategic perspective, Anlong is committed to becoming a leading enterprise in China's gene drug field. After years of investment, the company has achieved strategic expansion on two major technology platforms: gene therapy and small nucleic acid drugs. Collaborations with multiple listed companies in China have not only honed the R&D and clinical teams but also validated the company'sLiver-targeted delivery systemtechnical strength; while cooperation with overseas enterprises further proves itsExtrahepatic Targeted Delivery Capability, providing strong support for its proprietary products to enter international markets such as Europe and the United States. While expanding into international markets, Anlong Biotech retains the rights to the Greater China market, ensuring that it can continue to provide high-value innovative therapies to Chinese patients in the future.

Currently, China's biopharmaceutical industry, after experiencing fluctuations, is now leveraging its cooperation with European and American multinational pharmaceutical companies.BDCooperation ushers in a recovery opportunity. However, to truly grow into a player with international competitiveness,BiopharmaChinese enterprises not only need to possess cross-platform R&D capabilities and the ability to continuously produce hit products, but also need to deeply cultivate the Chinese market and master the commercialization capability of self-developed products. Anlong's breakthrough from gene therapy to nucleic acid drugs, though difficult, fully demonstrates its cross-platform R&D strength; while cooperation with foreign companies highlights the company’s profound understanding of domestic and international pharmaceutical markets and its commercial potential. Looking ahead, Anlong will continue to focus on the needs of the Chinese market, showcasing its business transformation capabilities, and steadily move towards its grand goal of becoming a leading enterprise in China’s gene drug industry.